Interpace Diagnostics (IDXG) Reports Q3 Loss of $0.11, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Bernstein on Crypto: 'Clarity fails - what next?'
Interpace Diagnostics Reports Third Quarter 2018 Financial Results, Business Progress and Recent Accomplishments
November 13, 2018 4:18 PM ESTConference Call Tuesday, November 13, 2018 at 4:30 pm ET
PARSIPPANY, NJ,, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and management, today announced financial results and business progress for the quarter ended September 30, 2018, as well as recent accomplishments.
Topline highlights include:
Expanded Guidance of Revenues for the Year to a Range between $21 and $22 MillionRevenue Grew to $5.8 Million in the Third Quarter... More